Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease.

BMJ (Clinical research ed.) - 19 Jun 2017

Cohen Benjamin L, Sachar David B

Abstract excerpt

The treatment of inflammatory bowel disease (IBD)-ulcerative colitis (UC) and Crohn's disease (CD)-has evolved beyond surgery with the introduction of biologic agents, primarily antibodies against mediators of inflammation and cell attraction. Anti-tumor necrosis factor (TNF) agents have been the first line treatment for moderate to severe ulcerative colitis and Crohn's disease for more than 15 years. During that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Genetic Predisposition to Disease
Share to Inflammatory Bowel Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Infliximab

Share to Molecular Targeted Therapy

Share to Treatment Outcome

Share to Tumor Necrosis Factor-alpha

Share to United States

Source

Identifiers

PMID: 28630047
DOI: 10.1136/bmj.j2505

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease.PMID 28630047Read ↗

Immunomodulators in inflammatory bowel disease: an emerging role for biologic agents.Semantic proximity Read ↗

New therapeutic strategies for treatment of inflammatory bowel diseaseSemantic proximity Read ↗

Advances in the pathogenesis and treatment of IBD.Semantic proximity Read ↗

Inflammatory bowel disease: new insights into pathogenesis and treatment.Semantic proximity Read ↗

Update in the management of extraintestinal manifestations of inflammatory bowel disease.Semantic proximity Read ↗

Review article: a critical approach to new forms of treatment of Crohn's disease and ulcerative colitis.Semantic proximity Read ↗

Future therapies for inflammatory bowel disease.Semantic proximity Read ↗

State of the art: IBD therapy and clinical trials in IBD.Semantic proximity Read ↗

Thiopurines in inflammatory bowel disease: new strategies for optimization of pharmacotherapy?Semantic proximity Read ↗

Joint involvement in inflammatory bowel disease: managing inflammation outside the digestive system.Semantic proximity Read ↗

JAK selectivity: more precision less troublesSemantic proximity Read ↗

Treatment of inflammatory bowel disease from the immunological perspective.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.